Navigation Links
Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes

hibitors. The Company's own R&D efforts and those of its numerous research partners utilizing modulators of SIRT1 (a human sirtuin) have extended the SIRT knowledge base significantly in recent years. Elixir is also actively pursuing drug discovery efforts focused on other key targets, such as AMP-activated kinase (AMPK), which Elixir has shown to be implicated in the regulation of aging and metabolism in a variety of organisms.

More information about Elixir is available at http://www.elixirpharm.com/

Contact

Elixir Pharmaceuticals
William Heiden, 617-995-7000
or
Media:
Burns McClellan for Elixir Pharmaceuticals
Justin Jackson
jjackson@burnsmc.com
or
Jason Farber
jfarber@burnsmc.com
or
Investors:
Juliane Snowden
jsnowden@burnsmc.com
or
Nicki Kahner
nkahner@burnsmc.com
212-213-0006


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
2. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:12/2/2008)...if., Dec. 2 TorreyPines Therapeuti...e results from a 26 patient Phase II trial evaluat...tomia, or dry mouth, in patients with Sjogren,s sy...istically significant increase in salivary flow pr...0 mg, 15 mg, and 20 mg. These doses were safe and ...
(Date:12/2/2008)... Dec. 2 Horizon Therapeutics, Inc....ay announced that two pivotal,Phase 3 trials eval... HZT-501,met all primary endpoints. HZT-501, a n...containing ibuprofen and famotidine, demonstrated ...dence of non-steroidal,anti-inflammatory drug (NS...
(Date:12/2/2008)..., Dec. 2 Micromet, Inc. ...eloping novel, proprietary antibodies for the trea...ses, today announced that it has entered into an a...Facility (CEFF) with Kingsbridge Capital Limited, ...e agreement, Kingsbridge has committed to provide ...
(Date:12/1/2008)... 2 New research has fou... computed tomography (CT) scanner in an emergency ...ke victims who receive a potentially life-saving t... Shore Medical Center (NSMC)-Salem Hospital in Sal...eeting of the Radiological Society of North Americ...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3NCPA Applauds U S House Vote in Favor of H R 6331 22698 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 2New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 3New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 4New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 5New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 6New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 7New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 8New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 9Drug Coated Stents Reduce Repeat Artery Procedures 22693 1Drug Coated Stents Reduce Repeat Artery Procedures 22693 2Drug Coated Stents Reduce Repeat Artery Procedures 22693 3Certain anti cancer agents could be harmful to patients with heart disease 22689 1Certain anti cancer agents could be harmful to patients with heart disease 22689 2Certain anti cancer agents could be harmful to patients with heart disease 22689 3
...ON VALLEY, Pa.--(BUSINESS WIRE)--Apr 12, 2007 - Im...at the American,Association for Cancer Research (A...5 to 18. The Company will feature,Immunicon Pharma...at Kit and the new EasyCount(TM) System at booth 1...opment and clinical,trial testing services to some...
...c found to dramatically reduce the risk of cancer,...estinal stromal,tumors (GIST) , * Patients receivi...c , * Global regulatory submissions planned for us...ollowing surgery to remove,primary tumor , * Glive...ts with,advanced metastatic or inoperable Kit-posi...
Other Medicine Technology:Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 2Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 3Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 5Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 6
(Date:12/2/2008)... Zicam Cold & Flu Companion uses loca...tep ahead of cold and flu. , ...Matrixx Initiatives, Inc., makers of Zicam® Co...® Cold & Flu Companion mobile application ...oid-powered phone. The same mobile application wil...
(Date:12/2/2008)...Call to Action Highlights Need to Reduce Dispariti...nal Efforts , , BETHESDA, Md., Dec. 2 /PRN...s Diseases, (NFID) S.T.O.P. (Share. Teach. Outre...f many of the nation,s leading medical and advocac...to improve adolescent meningococcal vaccination ra...
(Date:12/2/2008)...Dec. 2 MedPro Imaging, a premier p... announced the appointment of three,new ultrasoun... aggressive,expansion. The company also announce...cilities due to substantial growth throughout 2008...e president of Sales and Marketing in,February of...
(Date:12/2/2008)...wellness services available to seniors , , ... Alliance Plan (HAP) is adding acupuncture and chi...Benefit for Medicare Advantage members beginning J...promote wellness encourages Medicare beneficiaries...e putting money back in their wallets. , , ...
Breaking Medicine News(10 mins):Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 2Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 2Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 4Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 3
...tes in the US are stepping up their efforts to for...ds of mercury emissions.// Throughout the Northe...alth concern. Mercury is a metal that occurs natur...seous form when coal is burned in electrical gener...
...in Rajasthan - is all set to travel to war-hit Leb...ts from the Bhagwan Mahaveer Viklang Sahayta Samit...vitation of the Indian contingent of the UN peacek...SS general secretary S.R. Mehta said. The team w...
...stakes made by medical secretaries in India have b...h hospitals// from being outsourced to India and t...tional Health Service (NHS) have outsourced medica...re considering the option to cut budgetary deficit...
...disease in western Bangladesh's Kushtia district i...ng people// as the number of patients rises everyd... more than 50 people are being treated at the hosp...ents is growing day by day, The Daily Star reporte...
Other Medicine News:Health News:US States Get Ready to Fight Mercury Pollution 2Health News:Jaipur Foot Takes Off for Lebanon 2Health News:Outsourcing of UK Hospital Records to India Opposed 2
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: